Physician profile
Robert M Conry
NPI 1548203235
$142,532.66
in general payments reported to CMS, 2019-2025
37 companies · $1,693 in 2025
The $1,693 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $131K · 2020: $4,475 · 2021: $877 · 2022: $1,955 · 2023: $958 · 2024: $1,999 · 2025: $1,693.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,365 · Long Term Medical Supply Or Device Loan: $2,165 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $120.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,364.62 |
| Long Term Medical Supply Or Device Loan | $2,165.10 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $120.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $39,277.68 | 2019-2025 | |
| Array Biopharma INC | $37,315.62 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Merck Sharp & Dohme LLC | $25,725.90 | 2019-2025 | Keytruda, Lynparza, Welireg |
| E.R. Squibb & Sons, L.L.C. | $17,144.69 | 2019-2024 | Opdualag |
| Genzyme Corporation | $11,812.58 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $4,943.32 | 2019-2023 | Libtayo |
| Pfizer INC. | $3,690.24 | 2020-2025 | |
| Celgene Corporation | $1,091.48 | 2022-2025 | Reblozyl, Opdivo, Opdualag |
| Daiichi Sankyo INC. | $166.74 | 2022-2025 | Enhertu |
| Gilead Sciences, INC. | $151.92 | 2024-2025 | Trodelvy |
| Janssen Biotech, INC. | $131.03 | 2022-2025 | Rybrevant, Darzalex, Tecvayli |
| Galt Pharmaceuticals, LLC | $128.37 | 2023 | Oravig, Orphengesic Forte |
| Abbvie INC. | $117.83 | 2024-2025 | |
| Pharmacyclics LLC, An Abbvie Company | $106.83 | 2022-2023 | Imbruvica |
| Deciphera Pharmaceuticals INC. | $100.99 | 2022-2025 | Qinlock, Romvimza |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $76.25 | 2022-2025 | Jemperli, Ojjaara, Blenrep |
| Astrazeneca Pharmaceuticals LP | $69.72 | 2022-2024 | Enhertu, Calquence |
| Takeda Pharmaceuticals U.S.A., INC. | $62.52 | 2023-2025 | Ninlaro |
| Eisai INC. | $55.28 | 2022-2024 | |
| Seagen INC. | $52.42 | 2022 | |
| Stemline Therapeutics INC. | $52.40 | 2025 | Orserdu |
| Kite Pharma, INC. | $28.97 | 2023 | Yescarta |
| Exelixis INC. | $27.39 | 2022 | |
| Aveo Pharmaceuticals, INC. | $22.37 | 2023 | Fotivda |
| Taiho Oncology, INC. | $22.09 | 2022 | |
| Karyopharm Therapeutics INC. | $21.97 | 2022 | |
| Blueprint Medicines Corporation | $21.48 | 2023 | Ayvakit |
| Genentech USA, INC. | $20.74 | 2023 | Venclexta |
| Adc Therapeutics America, INC. | $17.20 | 2022 | |
| Global Blood Therapeutics, INC. | $16.78 | 2022 | |
| Rigel Pharmaceuticals, INC. | $16.25 | 2022 | |
| Beone Medicines USA, INC. | $15.92 | 2025 | Brukinsa |
| Agios Pharmaceuticals, INC. | $13.89 | 2022 | |
| Emd Serono, INC. | $13.80 | 2022 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Conry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.